Wednesday, May 4, 2011
PolyMedix Inc., of Radnor, Pa., presented data from two Phase Ib/II trials of PMX-60056, a synthetic small molecule designed to reverse the anticoagulation activity of heparin and low molecular weight heparins. The data suggested that both heparin and tinzaparin appear to bind on a one-to-one molecular basis with PMX-60056, which could simplify dosing in future trials. The compound is in a Phase II trial to assess the safety and efficacy of reversing heparin in patients undergoing percutaneous coronary intervention procedures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.